Chinese biopharma received 28% of global upfront licensing payments through June 2025. Amber Tong, Jinshan Hong, and Spe Chen cover the latest shift in drug development and biopharma deals from China. Biopharma deal data from DealForma. Read it here
Chinese biopharma received 28% of global upfront licensing payments through June 2025. Amber Tong, Jinshan Hong, and Spe Chen cover the latest shift in drug development and biopharma deals from China. Biopharma deal data from DealForma. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
